Remote Ischemic Perconditioning Attenuates Adverse Cardiac Remodeling and Preserves Left Ventricular Function in a Rat Model of Reperfused Myocardial Infarction
Overview
Authors
Affiliations
Aims: Remote ischemic conditioning (RIC) is considered a potential clinical approach to reduce myocardial infarct size and ameliorate adverse post-infarct left ventricular (LV) remodeling, however the mechanisms are unknown. The aim was to clarify the impact of RIC on Neuregulin-1 (NRG-1)/ErbBs expression, inflammation and LV hemodynamic function.
Methods And Results: Male Sprague-Dawley rats were subjected to 30 min occlusion of the left coronary artery (LCA) followed by 2 weeks of reperfusion and separated into three groups: (1) sham operated (without LCA occlusion); (2) Myocardial ischemia/reperfusion (MIR) and (3) remote ischemic perconditioning group (MIR + RIPerc). Cardiac structural and functional changes were evaluated by echocardiography and on the isolated working heart system. The level of H3K4me3 at the NRG-1 promoter, and both plasma and LV tissue levels of NRG-1 were assessed. The expression of pro-inflammatory cytokines, ECM components and ErbB receptors were assessed by RT-qPCR. MIR resulted in a significant decrease in LV function and enlargement of LV chamber. This was accompanied with a decrease in the level of H3K4me3 at the NRG-1 promoter. Consequently NRG-1 protein levels were reduced in the infarcted myocardium. Subsequently, an upregulated influx of CD68+ macrophages, high expression of MMP-2 and -9 as well as an increase of IL-1β, TLR-4, TNF-α, TNC expression were observed. In contrast, RIPerc significantly decreased inflammation and improved LV function in association with the enhancement of NRG-1 levels and ErbB3 expression.
Conclusions: These findings may reveal a novel anti-remodeling and anti-inflammatory effect of RIPerc, involving activation of NRG-1/ErbB3 signaling.
Marksteiner J, Dostal C, Ebner J, Szabo P, Podesser B, Baydar S Sci Rep. 2025; 15(1):8991.
PMID: 40089543 DOI: 10.1038/s41598-025-92927-4.
Francisco J, Del Re D Antioxidants (Basel). 2023; 12(11).
PMID: 38001797 PMC: 10669026. DOI: 10.3390/antiox12111944.
Wang J, Du H, Sun Q, Wan W, Zhang H BMC Cardiovasc Disord. 2023; 23(1):571.
PMID: 37986153 PMC: 10662688. DOI: 10.1186/s12872-023-03604-1.
Boxhammer E, Paar V, Wernly B, Kiss A, Mirna M, Aigner A Cells. 2023; 12(19).
PMID: 37830583 PMC: 10571870. DOI: 10.3390/cells12192369.
Neuregulin-1β Improves Uremic Cardiomyopathy and Renal Dysfunction in Rats.
Sarkozy M, Watzinger S, Kovacs Z, Acar E, Marvanykovi F, Szucs G JACC Basic Transl Sci. 2023; 8(9):1160-1176.
PMID: 37791301 PMC: 10543921. DOI: 10.1016/j.jacbts.2023.03.003.